EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Sustained complete response achieved in a patient with advanced HER-2 positive gastric cancer after 4 years of chemotherapy-free treatment

Xinyu Tong, Jieqiong Peng, Bo Liu

Frontiers in Oncology · 14.04.2026 · 16

DOI: 10.3389/fonc.2026.1756461 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 14.04.2026. Verfasst von Xinyu Tong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gastric cancer ranks fifth in both global incidence and mortality rates, with over half of the newly diagnosed cases worldwide occurring in China. Most patients are diagnosed at advanced stages, making surgical resection unfeasible. As a result, current treatment primarily relies on chemotherapy-based multimodal therapies. However, with ongoing research, chemotherapy-free treatment strategies are gaining increasing attention and have emerged as a promising avenue for the treatment of gastric cancer. Case presentation A 42-year-old male was diagnosed with stage IV gastric adenocarcinoma and multiple liver metastases due to abdominal bloating. The patient was enrolled in a clinical study and received a combination of KN026 and KN046 targeted therapy with immunotherapy. After two years of treatment, a complete response was achieved.

Conclusions

The combination of anti-HER-2 bispecific targeting therapy and PD-1/CTLA-4 bispecific immunotherapy demonstrated promising efficacy and a favorable safety profile in this patient with advanced HER2-positive gastric cancer, achieving durable complete response without chemotherapy. This case provides a rationale for further exploring chemotherapy-free strategies using dual bispecific antibodies in carefully selected patients.

Schlagwörter

Stichwörter der Autor:innen

HER-2 positiveHER2 bispecific antibody(BsAb)PD-L1/CTLA-4 bispecific antibodychemotherapy-freecomplete response

Autor:innen und Institutionen

  • Department of Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

Zitieren

APA

Tong, X., Peng, J., & Liu, B. (2026). Case Report: Sustained complete response achieved in a patient with advanced HER-2 positive gastric cancer after 4 years of chemotherapy-free treatment. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1756461

Vancouver

Tong X, Peng J, Liu B. Case Report: Sustained complete response achieved in a patient with advanced HER-2 positive gastric cancer after 4 years of chemotherapy-free treatment. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1756461

BibTeX
@article{Tong2026,
  author = {Tong, Xinyu and Peng, Jieqiong and Liu, Bo},
  title = {Case Report: Sustained complete response achieved in a patient with advanced HER-2 positive gastric cancer after 4 years of chemotherapy-free treatment},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1756461}
}
Kostenlos starten →